Bifunctional Antisense Oligonucleotides Provide a Trans-acting Splicing Enhancer That Stimulates SMN2 Gene Expression in Patient Fibroblasts

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2003 Mar 19

PMID 12642665

Citations 119

Authors

Leigh A Skordis

Matthew G Dunckley

Baigong Yue

Ian C Eperon

Francesco Muntoni

Affiliations

Soon will be listed here.

Abstract

The multiplicity of proteins compared with genes in mammals owes much to alternative splicing. Splicing signals are so subtle and complex that small perturbations may allow the production of new mRNA variants. However, the flexibility of splicing can also be a liability, and several genetic diseases result from single-base changes that cause exons to be skipped during splicing. Conventional oligonucleotide strategies can block reactions but cannot restore splicing. We describe here a method by which the use of a defective exon was restored. Spinal muscular atrophy (SMA) results from mutations of the Survival Motor Neuron (SMN) gene. Mutations of SMN1 cause SMA, whereas SMN2 acts as a modifying gene. The two genes undergo alternative splicing with SMN1, producing an abundance of full-length mRNA transcripts, whereas SMN2 predominantly produces exon 7-deleted transcripts. This discrepancy is because of a single nucleotide difference in SMN2 exon 7, which disrupts an exonic splicing enhancer containing an SF2ASF binding site. We have designed oligoribonucleotides that are complementary to exon 7 and contain exonic splicing enhancer motifs to provide trans-acting enhancers. These tailed oligoribonucleotides increased SMN2 exon 7 splicing in vitro and rescued the incorporation of SMN2 exon 7 in SMA patient fibroblasts. This treatment also resulted in the partial restoration of gems, intranuclear structures containing SMN protein that are severely reduced in patients with SMA. The use of tailed antisense oligonucleotides to recruit positively acting factors to stimulate a splicing reaction may have therapeutic applications for genetic disorders, such as SMA, in which splicing patterns are altered.

Citing Articles

30 Years Since the Proposal of Exon Skipping Therapy for Duchenne Muscular Dystrophy and the Future of Pseudoexon Skipping.

Matsuo M Int J Mol Sci. 2025; 26(3).

PMID: 39941071 PMC: 11818380. DOI: 10.3390/ijms26031303.

Patient-specific responses to splice-modifying treatments in spinal muscular atrophy fibroblasts.

Signoria I, Zwartkruis M, Geerlofs L, Perenthaler E, Faller K, James R Mol Ther Methods Clin Dev. 2024; 32(4):101379.

PMID: 39655308 PMC: 11626024. DOI: 10.1016/j.omtm.2024.101379.

The bench to bedside journey of tricyclo-DNA antisense oligonucleotides for the treatment of Duchenne muscular dystrophy.

Blitek M, Phongsavanh X, Goyenvalle A RSC Med Chem. 2024; 15(9):3017-3025.

PMID: 39309360 PMC: 11411614. DOI: 10.1039/d4md00394b.

Identification of a novel alternative splicing isoform of the Hippo kinase STK3/MST2 with impaired kinase and cell growth suppressing activities.

Rodrigues A, Fiore A, Guardia G, Tomasin R, Azevedo Reis Teixeira A, Giordano R Oncogene. 2024; 43(39):2938-2950.

PMID: 39174858 DOI: 10.1038/s41388-024-03104-2.

Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade.

Cantara S, Simoncelli G, Ricci C Int J Mol Sci. 2024; 25(9).

PMID: 38732027 PMC: 11083842. DOI: 10.3390/ijms25094809.

References

Galderisi U, Cascino A, Giordano A . Antisense oligonucleotides as therapeutic agents. J Cell Physiol. 1999; 181(2):251-7. DOI: 10.1002/(SICI)1097-4652(199911)181:2<251::AID-JCP7>3.0.CO;2-D. View

Olive M, Gesnel M, Breathnach R . hnRNP A1 recruited to an exon in vivo can function as an exon splicing silencer. Mol Cell Biol. 1998; 19(1):251-60. PMC: 83883. DOI: 10.1128/MCB.19.1.251. View

Fairbrother W, Yeh R, Sharp P, Burge C . Predictive identification of exonic splicing enhancers in human genes. Science. 2002; 297(5583):1007-13. DOI: 10.1126/science.1073774. View

Mercatante D, Sazani P, Kole R . Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases. Curr Cancer Drug Targets. 2002; 1(3):211-30. DOI: 10.2174/1568009013334124. View

Black D . Activation of c-src neuron-specific splicing by an unusual RNA element in vivo and in vitro. Cell. 1992; 69(5):795-807. DOI: 10.1016/0092-8674(92)90291-j. View

Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L . Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995; 80(1):155-65. DOI: 10.1016/0092-8674(95)90460-3. View

Cartegni L, Maconi M, Morandi E, Cobianchi F, Riva S, Biamonti G . hnRNP A1 selectively interacts through its Gly-rich domain with different RNA-binding proteins. J Mol Biol. 1996; 259(3):337-48. DOI: 10.1006/jmbi.1996.0324. View

Liu Q, Dreyfuss G . A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 1996; 15(14):3555-65. PMC: 451956. View

Chabot B . Directing alternative splicing: cast and scenarios. Trends Genet. 1996; 12(11):472-8. DOI: 10.1016/0168-9525(96)10037-8. View

10.

McAndrew P, Parsons D, Simard L, Rochette C, Ray P, Mendell J . Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet. 1997; 60(6):1411-22. PMC: 1716150. DOI: 10.1086/515465. View

11.

Coovert D, Le T, McAndrew P, Strasswimmer J, Crawford T, Mendell J . The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997; 6(8):1205-14. DOI: 10.1093/hmg/6.8.1205. View

12.

Schrank B, Gotz R, Gunnersen J, Ure J, Toyka K, Smith A . Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A. 1997; 94(18):9920-5. PMC: 23295. DOI: 10.1073/pnas.94.18.9920. View

13.

Battaglia G, Princivalle A, Forti F, Lizier C, Zeviani M . Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system. Hum Mol Genet. 1997; 6(11):1961-71. DOI: 10.1093/hmg/6.11.1961. View

14.

Mattaj I . Ribonucleoprotein assembly: clues from spinal muscular atrophy. Curr Biol. 1998; 8(3):R93-5. DOI: 10.1016/s0960-9822(98)70055-7. View

15.

Liu H, Zhang M, Krainer A . Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins. Genes Dev. 1998; 12(13):1998-2012. PMC: 316967. DOI: 10.1101/gad.12.13.1998. View

16.

Taylor J, Thomas N, Lewis C, Abbs S, Rodrigues N, Davies K . Correlation of SMNt and SMNc gene copy number with age of onset and survival in spinal muscular atrophy. Eur J Hum Genet. 1998; 6(5):467-74. DOI: 10.1038/sj.ejhg.5200210. View

17.

Parsons D, McAndrew P, Iannaccone S, Mendell J, Burghes A, Prior T . Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. Am J Hum Genet. 1998; 63(6):1712-23. PMC: 1377643. DOI: 10.1086/302160. View

18.

Cartegni L, Chew S, Krainer A . Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet. 2002; 3(4):285-98. DOI: 10.1038/nrg775. View

19.

Lorson C, Hahnen E, Androphy E, Wirth B . A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999; 96(11):6307-11. PMC: 26877. DOI: 10.1073/pnas.96.11.6307. View

20.

Monani U, Lorson C, Parsons D, Prior T, Androphy E, Burghes A . A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999; 8(7):1177-83. DOI: 10.1093/hmg/8.7.1177. View